Guillain-Barré syndrome associated with Coronavirus disease 2019: A case from Nepal

Roshan Aryal1, Shivaji Karki1, Shreesti Rajbhandari1

  • 1Maharajgunj Medical Campus Institute of Medicine Tribhuvan University Kathmandu Nepal.

Clinical Case Reports
|March 31, 2022
PubMed

Insights

A rare neurological complication, Guillain-Barré syndrome, has been linked to Coronavirus disease 2019 (COVID-19). This case report details a patient in Nepal who developed Guillain-Barré syndrome following COVID-19 infection.

Area of Science:

  • Neurology
  • Infectious Diseases
  • Immunology

Background:

  • Coronavirus disease 2019 (COVID-19) is a global pandemic caused by SARS-CoV-2.
  • Guillain-Barré syndrome (GBS) is an autoimmune disorder affecting peripheral nerves.
  • GBS is a known potential post-infectious complication of various pathogens.

Observation:

  • This report describes a case of GBS in a patient from Nepal.
  • The patient developed GBS subsequent to a confirmed COVID-19 diagnosis.

Findings:

  • The case demonstrates a correlation between COVID-19 infection and the development of Guillain-Barré syndrome.
  • This association highlights GBS as a rare neurological complication of COVID-19.

Implications:

  • Understanding the neurological complications of COVID-19 is crucial for patient management.
  • Further research is warranted to elucidate the mechanisms linking SARS-CoV-2 and GBS.
  • This case contributes to the global understanding of COVID-19's diverse clinical manifestations.

Related Concept Videos

Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
16.1K
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
347
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
257
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
217
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
483